Homology Medicines Inc (FIXX)

[Renee]

FIXX: effective March 25,2024 a one for 18 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

[Monksdream]

FIXX 10Q due March 15

[glenn1919]

FIXX..................................https://stockcharts.com/h-sc/ui?s=FIXX&p=W&b=5&g=0&id=p86431144783

[Banjo50]

IS THIS STOCK A SCAM OR WHAT ??? I WANT THE TRUTH!!!

[TrendTrade2016]

FIXX HERES THE BREAKOUT

[KOmani]

Unsure if they already have a buyer.

I feel like they may have had the results and went to Pfizer who said they didn't want to invest more or they do not want to be diluted down.

I have heard others say they have held from $3-4 and want profit from that point, but I doubt that is likely.

However, I do think $3ish is possible...

We shall see, perhaps they have some offer and just want to see if their is more interest.

[TrendTrade2016]

An explosive bottom play. See ya at 2.25

[TrendTrade2016]

FIXX IS GOING RIP IT UP NEXT WEEK...WATCH THE MAGIC!!

[TrendTrade2016]

watch this beast fly

[DK11]

Adding more is a very good idea, I see this doing very well

[KOmani]

Seems they tried to dip out some shares.

Wasn't much of a dip, but maybe there are some others quietly loading.

Over $1.17 and probably add some more.

[KOmani]

Pretty sure what happened is that they went to Pfizer about raising more funds and they were told no.

Seems cheap at $1ish, but seems like market disagrees that they are worth cash less liabilities.

Still, is there really no one interested in make a possible double from here?

Unsure if it is being capped hoping to get some sellers.

[DK11]

I think the fixx is in.

[AJ Freely]

$FIXX- Up 19% Pre-Market/ Current Price $1.13
July 25, 2023 the “Company reduced it's workforce by approximately 80 employees as well as some top management at a cost of $6.3 in severance payments

[Monksdream]

Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU
July 27 2023 - 04:05PM
GlobeNewswire Inc.
Print
Share On Facebook

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has completed a review of its business, and the Board of Directors has approved a plan to evaluate strategic alternatives to maximize shareholder value. Earlier today, Homology reported encouraging initial data from the first dose level in the Phase 1, dose-escalation trial evaluating gene editing candidate HMI-103 in adults with classical phenylketonuria (PKU), which showed it was generally well-tolerated in all three participants and resulted in a meaningful reduction in plasma phenylalanine (Phe) in two participants as of the data cut-off date of July 26, 2023. Despite these encouraging data, based on the current financing environment and Homology’s anticipated clinical development timelines, Homology will not be further developing its programs and will be instituting a related reduction in force while it explores options for the Company and its assets, including HMI-103. Homology has retained TD Cowen as its strategic financial advisor.

[kzivann]

Volume after hours on news.

FIXX

[Market Chess]

Buy more FIXX the FDA didn't completely stop the trials, it’s merely a temporary hold. They also have two more ongoing
clinical trials on rare genetic diseases.

[bryyep649]

Looking better here

[hercules16]

Interesting thread. 30 posts and 15 on one day. I have two thoughts on FIXX:
(1) Seems possibly quite cheap. 12/14/20: H.C. Wainwright analyst Patrick Trucchio took over coverage of Homology Medicines and kept a Buy rating on the shares with a $30 price target. The analyst views Homology as a differentiated gene therapy and editing platform company

(2) They use spike proteins to insert their gene editing technolgy? And the coranavirus vaccines tell our immune systems to disable spike proteins? Does their technology still work in a post vaccine world? (And I understand little about these things and a little knowledge can be very dangerous)

If I knew which of these thoughts was right I would know whether to buy or not. Probably will buy a little tommorrow if it holds today low (6.80 ish) anyway. Edit: the heck with it I'll buy a little right now (afterhours) for 7.19. Would like to see it do a morningstar doji.

[Rockurstocks]

Ready to break HOD
$FIXX

[MWM]

https://www.linkedin.com/posts/homology-medicines-inc%2E_homology-medicines-announces-plans-for-three-activity-6752633584168841216-oRfu

[MWM]

$PFE buys at $12 a share, I say this is a pretty good level to start a position...

Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc.
BEDFORD, Mass., November 9, 2020 – Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Pfizer Inc. (NYSE: PFE) has agreed to make a $60 million equity investment in Homology. Pfizer has agreed to purchase 5,000,000 of Homology’s common stock at a price of $12.00 per share, as part of the Pfizer Breakthrough Growth Initiative, which was announced earlier this year. The purchase by Pfizer is expected to close on or about November 10, 2020.

“With the positive clinical data from the dose-escalation phase of our pheNIX Phase 1/2 trial for adults with phenylketonuria (PKU) and our plans to move to the expansion phase of the trial, both of which we announced last week, we believe Pfizer’s investment in Homology is a testament to their enthusiasm for our PKU gene therapy and gene editing programs to treat people living with this disease,” stated Arthur Tzianabos, Ph.D., President and Chief Executive Officer of Homology Medicines.

“Pfizer Rare Disease has a 30-year heritage of developing treatment options for patients with some of the greatest unmet needs, including in the area of rare metabolic disorders,” said Seng Cheng, Ph.D., Senior Vice President and Chief Scientific Officer of Pfizer’s Rare Disease Research Unit. “Our investment in Homology represents another example of our commitment to collaborate with the biotechnology community. We believe gene therapy could help provide a potentially transformational therapeutic option for patients living with PKU and is a good strategic fit with our rAAV-associated gene therapy portfolio.”

In connection with the investment, Pfizer’s Dr. Cheng will join Homology’s Scientific Advisory Board to participate in matters related to the development of the Company’s PKU product candidates: HMI-102 gene therapy candidate for adults with PKU and HMI-103 gene editing candidate for pediatric patients with PKU. Additionally, the Company has granted Pfizer a right of first refusal on future transactions involving these programs.

Homology intends to use the net proceeds of the offering to help fund its ongoing and planned PKU clinical trials, as well as the Company’s central nervous system (CNS) programs. Based on current projections, together with the anticipated proceeds of $60 million from the Pfizer equity investment, Homology expects cash resources to fund operations into the third quarter of 2022.

About HMI-102 Gene Therapy and HMI-103 Gene Editing Product Candidates

HMI-102 is an investigational gene therapy in clinical development for the treatment of phenylketonuria (PKU) in adults. HMI-102 is designed to encode the PAH gene, which is mutated in people with PKU, delivered via the liver-tropic AAVHSC15 vector. Homology has received Fast Track Designation and orphan drug designation for HMI-102 from the U.S. Food and Drug Administration (FDA), and orphan drug designation from the European Medicines Agency (EMA). HMI-103 is an investigational, nuclease-free gene editing product candidate in IND-enabling studies for pediatric patients with PKU, whose livers are rapidly dividing. By delivering a functional copy of the PAH gene to replace the mutated copy in the genome, gene editing is the best approach for a potential one-time treatment for this population.

About Phenylketonuria (PKU)

PKU is a rare inborn error of metabolism caused by a mutation in the PAH gene. PKU results in a loss of function of the enzyme phenylalanine hydroxylase, which is responsible for the metabolism of phenylalanine (Phe), an amino acid obtained exclusively from the diet. If left untreated, toxic levels of Phe can accumulate in the blood and result in progressive and severe neurological impairment. Currently, there are no treatment options for PKU that target the underlying genetic cause of the disease. According to the National PKU Alliance, PKU affects nearly 16,500 people in the U.S. with approximately 350 newborns diagnosed each year. The worldwide prevalence of PKU is estimated to be 50,000 people.

About Homology Medicines, Inc.

Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases, and intellectual property covering its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines. For more information, please visit www.homologymedicines.com.

[MWM]

CFO is from PFE and Shire and the rest of management is all from Shire...

Shire
Biotechnology company

Shire plc was a Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019. Wikipedia
Headquarters: Lexington, MA
CEO: Flemming Ørnskov (Apr 30, 2013–)
Revenue: 15.16 billion USD
Number of employees: 23,044 (2018)
Parent organization: Takeda Pharmaceutical Company

[Rockurstocks]

Stupid me... wow Pfizer. This is great

[MWM]

I'm talking about where management are from...

Albert Seymour

Chief Scientific Officer at Homology Medicines



Company Name Homology Medicines

Dates Employed Apr 2016 – Present
Employment Duration4 yrs 10 mos
Shire Pharmaceuticals
SVP, Head of Global Research and Nonclinical Development
Company Name Shire Pharmaceuticals
Dates Employed Mar 2014 – Mar 2016
Employment Duration2 yrs 1 mo

Shire HGT
Vice President and Head of Discovery Research
Company NameShire HGT
Dates EmployedApr 2011 – Mar 2014
Employment Duration3 yrs

Pfizer
Company NamePfizer
Total Duration 13 yrs 10 mos
Title Senior Director of Medical Genetics, Orphan and Genetic Diseases Unit
Dates EmployedAug 2010 – May 2011
Employment Duration10 mos
Title Senior Director of Human Genetics and Biological Profiling
Dates EmployedAug 2007 – Sep 2010
Employment Duration3 yrs 2 mos
Title Director of Pharmacogenomics
Dates EmployedAug 1997 – Jul 2007
Employment Duration10 yrs

[Rockurstocks]

They must be adding employees.. 206 now

[Rockurstocks]

Read it wrong, 205 employees

[Rockurstocks]

Got it, had to get the app. 250 employees at homology all in the Boston area. Their employee size says 51-200, they got to update that!

[MWM]

Click on the employees

https://www.linkedin.com/company/homology-medicines-inc./

[Rockurstocks]

Not sure I’m able to see with the link

[MWM]

Research Linkedin look at where the employees are all from $FIXX

https://www.linkedin.com/search/results/people/?currentCompany=%5B%2215079527%22%5D&origin=COMPANY_PAGE_CANNED_SEARCH

[MWM]

Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative

First four investments of new program created to support clinical-stage biotechnology companies

New investments include companies focused on Oncology, Rare Disease, and Inflammation & Immunology

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that, during the second half of 2020, it invested a total of $120 million in four clinical-stage biotech companies as part of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is investing up to $500 million in biotechnology companies, providing funding and access to Pfizer’s scientific expertise to help ensure the continuity of promising clinical development programs of potential future strategic interest to Pfizer.


Pfizer’s initial PBGI investments include:

$10 million in Vancouver, BC-based ESSA Pharma (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
$25 million in Cambridge, Mass.-based Trillium Therapeutics (Nasdaq: TRIL), a clinical-stage immuno-oncology company focused on developing innovative therapies for the treatment of cancer. In addition, Jeff Settleman, Senior Vice President and Chief Scientific Officer of Pfizer’s Oncology Research & Development Group, was named to Trillium’s Scientific Advisory Board.
$25 million in Cambridge, Mass.-based Vedanta Biosciences, a privately held clinical-stage company focused on developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human microbiome-derived bacteria. In addition, Michael Vincent, Senior Vice President and Chief Scientific Officer of Pfizer’s Inflammation & Immunology Research Unit, will join Vedanta’s Scientific Advisory Board.
$60 million in Bedford, Mass.-based Homology Medicines (Nasdaq: FIXX), a clinical-stage genetic medicines company focused on treatments for rare genetic diseases with significant unmet medical needs. In addition, Seng Cheng, Senior Vice President and Chief Scientific Officer of Pfizer’s Rare Disease Research Unit, has joined Homology’s Scientific Advisory Board for matters related to Homology’s gene therapy and gene editing programs for phenylketonuria (PKU).
“Pfizer has a long history of collaborating across the healthcare ecosystem with the shared goal of turning great science into innovative new medicines,” said Debbie Baron, Senior Vice President of Business Development, Pfizer. “Our investments in Homology, Vedanta, Trillium, and ESSA reflect our commitment to find new and creative ways to leverage Pfizer’s resources to deliver breakthroughs to patients.”

Established in June 2020, the Pfizer Breakthrough Growth Initiative focuses on non-controlling equity investments primarily in public companies with small- to medium-sized market capitalizations and mature private companies that are developing clinical-stage assets aligned with Pfizer’s core areas of focus: Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines, and Hospital. In addition to equity, Pfizer looks to strengthen collaboration through participation on company and scientific advisory boards, as well as securing certain strategic rights when of mutual fit.

Biotechnology companies interested in learning more may contact [e-mail].

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice: The information contained in this release is as of January 12, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about the Pfizer Breakthrough Growth Initiative (PBGI) and Pfizer’s initial PBGI investments in ESSA Pharma, Trillium Therapeutics, Vedanta Biosciences and Homology Medicines, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development; uncertainties regarding the ability of the Pfizer Breakthrough Growth Initiative to identify investment candidates; uncertainties regarding the success of investments by the Pfizer Breakthrough Growth Initiative; uncertainties and variables inherent in business operating and financial performance, including, among other things, competitive developments and general economic, political, business, industry, regulatory and market conditions; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; uncertainties regarding the impact of COVID-19; and competitive developments.

[Rockurstocks]

Added calls
$FIXX

[MWM]

$FIXX love the news and connection with $PFE

Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc.

BEDFORD, Mass., November 9, 2020 – Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Pfizer Inc. (NYSE: PFE) has agreed to make a $60 million equity investment in Homology. Pfizer has agreed to purchase 5,000,000 of Homology’s common stock at a price of $12.00 per share, as part of the Pfizer Breakthrough Growth Initiative, which was announced earlier this year. The purchase by Pfizer is expected to close on or about November 10, 2020.

“With the positive clinical data from the dose-escalation phase of our pheNIX Phase 1/2 trial for adults with phenylketonuria (PKU) and our plans to move to the expansion phase of the trial, both of which we announced last week, we believe Pfizer’s investment in Homology is a testament to their enthusiasm for our PKU gene therapy and gene editing programs to treat people living with this disease,” stated Arthur Tzianabos, Ph.D., President and Chief Executive Officer of Homology Medicines.

“Pfizer Rare Disease has a 30-year heritage of developing treatment options for patients with some of the greatest unmet needs, including in the area of rare metabolic disorders,” said Seng Cheng, Ph.D., Senior Vice President and Chief Scientific Officer of Pfizer’s Rare Disease Research Unit. “Our investment in Homology represents another example of our commitment to collaborate with the biotechnology community. We believe gene therapy could help provide a potentially transformational therapeutic option for patients living with PKU and is a good strategic fit with our rAAV-associated gene therapy portfolio.”

In connection with the investment, Pfizer’s Dr. Cheng will join Homology’s Scientific Advisory Board to participate in matters related to the development of the Company’s PKU product candidates: HMI-102 gene therapy candidate for adults with PKU and HMI-103 gene editing candidate for pediatric patients with PKU. Additionally, the Company has granted Pfizer a right of first refusal on future transactions involving these programs.

Homology intends to use the net proceeds of the offering to help fund its ongoing and planned PKU clinical trials, as well as the Company’s central nervous system (CNS) programs. Based on current projections, together with the anticipated proceeds of $60 million from the Pfizer equity investment, Homology expects cash resources to fund operations into the third quarter of 2022.

About HMI-102 Gene Therapy and HMI-103 Gene Editing Product Candidates

HMI-102 is an investigational gene therapy in clinical development for the treatment of phenylketonuria (PKU) in adults. HMI-102 is designed to encode the PAH gene, which is mutated in people with PKU, delivered via the liver-tropic AAVHSC15 vector. Homology has received Fast Track Designation and orphan drug designation for HMI-102 from the U.S. Food and Drug Administration (FDA), and orphan drug designation from the European Medicines Agency (EMA). HMI-103 is an investigational, nuclease-free gene editing product candidate in IND-enabling studies for pediatric patients with PKU, whose livers are rapidly dividing. By delivering a functional copy of the PAH gene to replace the mutated copy in the genome, gene editing is the best approach for a potential one-time treatment for this population.

About Phenylketonuria (PKU)

PKU is a rare inborn error of metabolism caused by a mutation in the PAH gene. PKU results in a loss of function of the enzyme phenylalanine hydroxylase, which is responsible for the metabolism of phenylalanine (Phe), an amino acid obtained exclusively from the diet. If left untreated, toxic levels of Phe can accumulate in the blood and result in progressive and severe neurological impairment. Currently, there are no treatment options for PKU that target the underlying genetic cause of the disease. According to the National PKU Alliance, PKU affects nearly 16,500 people in the U.S. with approximately 350 newborns diagnosed each year. The worldwide prevalence of PKU is estimated to be 50,000 people.

About Homology Medicines, Inc.

Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases, and intellectual property covering its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines. For more information, please visit www.homologymedicines.com.

[MWM]

$FIXX Chart looks good

[MWM]

$FIXX Loading up here today

[trades2win]

This stock is ready to go !!!! Up in AH

[02opida]

Upcoming Virtual Events

The EveryLife Foundation Scientific Conference: December 15, 2020
H.C. Wainwright BioConnect Conference: January 11 - 14, 2021

[02opida]

9.98

[02opida]

morning Homology Med FIXX

[02opida]

Green

[02opida]

morning FIXX

[02opida]

lets Fly FIXX

[02opida]

omology Medicines Announces $60 Million Equity Investment from Pfizer Inc.

[02opida]

Homology Medicines Unveils New In Vivo Gene Therapy Development Program for Hunter Syndrome

[02opida]

Earnings Nov 9

[02opida]

Earnings Nov 9

[02opida]

https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=FIXX&insttype=&freq=&show=

[02opida]

https://www.stockwatch.com/News/Search?wire=0&symbolchanges=Y&symbol=FIXX®ion=U

[02opida]

Homology Medicines to Participate in Upcoming Conferences